Avalon Ventures XI Amends Janux Therapeutics Stake
Ticker: JANX · Form: SC 13D/A · Filed: Oct 25, 2024 · CIK: 1817713
| Field | Detail |
|---|---|
| Company | Janux Therapeutics, Inc. (JANX) |
| Form Type | SC 13D/A |
| Filed Date | Oct 25, 2024 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, sec-filing, pharmaceuticals
TL;DR
Avalon Ventures XI just updated their Janux Therapeutics filing - watch this space.
AI Summary
Avalon Ventures XI, L.P. and its affiliates have amended their Schedule 13D filing regarding Janux Therapeutics, Inc. as of October 25, 2024. The filing indicates a change in beneficial ownership, with Avalon Ventures XI, L.P. listed as a filer alongside other Avalon entities and individuals like Braden Bohrmann and Jay Lichter. The filing pertains to Janux Therapeutics, Inc., a company in the pharmaceutical preparations sector.
Why It Matters
This amendment signals a potential shift in control or investment strategy by a significant shareholder in Janux Therapeutics, which could impact the company's stock performance and future direction.
Risk Assessment
Risk Level: medium — Changes in beneficial ownership filings can indicate shifts in major investor sentiment or strategy, potentially affecting stock price.
Key Players & Entities
- Avalon Ventures XI, L.P. (company) — Filing entity
- Janux Therapeutics, Inc. (company) — Subject company
- Braden Bohrmann (person) — Group member
- Jay Lichter, Ph.D. (person) — Group member
- 20241025 (date) — Filing date
FAQ
What is the primary purpose of this SC 13D/A filing?
This filing is an amendment (Amendment No. 6) to a Schedule 13D, indicating a change in beneficial ownership of Janux Therapeutics, Inc. by Avalon Ventures XI, L.P. and its group members.
Who are the key entities involved in this filing?
The key entities are Janux Therapeutics, Inc. (the subject company) and Avalon Ventures XI, L.P., along with other affiliated Avalon entities and individuals such as Braden Bohrmann and Jay Lichter, Ph.D.
When was this amendment filed?
This amendment was filed on October 25, 2024.
What industry does Janux Therapeutics, Inc. operate in?
Janux Therapeutics, Inc. operates in the Pharmaceutical Preparations sector, with SIC code 2834.
Where is Janux Therapeutics, Inc. headquartered?
Janux Therapeutics, Inc. is headquartered in San Diego, CA, with its business address at 10955 Vista Sorrento Parkway, Suite 200, San Diego, CA 92130.
Filing Stats: 4,799 words · 19 min read · ~16 pages · Grade level 7.7 · Accepted 2024-10-25 17:28:42
Key Financial Figures
- $0.001 — ame of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 47103
Filing Documents
- tm2426876d1_sc13da.htm (SC 13D/A) — 252KB
- tm2426876d1_ex99a.htm (EX-99.A) — 7KB
- 0001104659-24-111544.txt ( ) — 262KB
Interest in Securities of the Issuer
Item 5. Interest in Securities of the Issuer
of the Statement is hereby amended and restated as follows
Item 5 of the Statement is hereby amended and restated as follows: (a)– (b). The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of October 24, 2024: Reporting Persons Shares Held Directly Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Beneficial Ownership Percentage of Class (6) Avalon Ventures (1) 1,828,127 1,828,127 1,828,127 1,828,127 3.5 % ABV SPV (2) 1,866,576 1,866,576 1,866,576 1,866,576 3.6 % ABV I (3) 354,118 354,118 354,118 354,118 0.7 % Avalon XI GP (1) 1,828,127 1,828,127 1,828,127 3.5 % ABV SPV GP (2) 1,866,576 1,866,576 1,866,576 3.6 % ABV GP (3) 354,118 354,118 354,118 0.7 % Kinsella (1) 1,828,127 1,828,127 1,828,127 3.5 % Levandov (1) 5,651 5,651 1,828,127 5,651 1,828,127 1,833,778 3.5 % Bohrmann (1) 1,828,127 1,828,127 1,828,127 3.5 % Lichter (1) (2) (3) (4) 41,497 41,497 4,048,821 41,497 4,048,821 4,090,318 7.8 % Reardon (2) (3) (5) 298,582 298,582 2,220,694 278,566 2,220,694 2,519,276 4.8 % Duron (3) 51,068 51,068 354,118 51,068 354,118 405,186 0.8 % Madigan (3) 59,6